# A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

> **NCT02019264** · PHASE4 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 14673 (actual)

## Conditions studied

- Cardiovascular Disease
- High Cardiovascular Risk
- Obesity
- Overweight
- Type 2 Diabetes

## Interventions

- **DRUG:** Lorcaserin hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02019264
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-24
- **Primary completion:** 2018-05-14
- **Final completion:** 2018-05-14
- **Target enrollment:** 14673 (ACTUAL)
- **Last updated:** 2019-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019264, "A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02019264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*